Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naïve metastatic castration-resistant prostate cancer at the prespecified interim analysis of PREVAIL, a phase 3, double-blind, randomized study. We evaluated the l...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Urol
Asıl Yazarlar: Beer, Tomasz M., Armstrong, Andrew J., Rathkopf, Dana, Loriot, Yohann, Sternberg, Cora N., Higano, Celestia S., Iversen, Peter, Evans, Christopher P., Kim, Choung-Soo, Kimura, Go, Miller, Kurt, Saad, Fred, Bjartell, Anders S., Borre, Michael, Mulders, Peter, Tammela, Teuvo L., Parli, Teresa, Sari, Suha, van Os, Steve, Theeuwes, Ad, Tombal, Bertrand
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570461/
https://ncbi.nlm.nih.gov/pubmed/27477525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.07.032
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller